Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 940-123-5 | CAS number: 866889-74-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: LD50 > 2000 mg/kg bw, OECD Guideline 423, GLP compliant
Acute dermal toxicity: LD50 > 2000 mg/kg bw, Appraisal of the Safety of Chemicals in Foods, Drugs & Cosmetics, pre-GLP; read-across from Amide, C8-18 and C18-unsatd., N,N-bis(hydroxyethyl)
Acute inhalation toxicity: not necessary due to exposure considerations
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013-10-09 to 2013-12-04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study, GLP
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: Approx. 9 weeks
- Weight at study initiation: 215 - 241 g
- Fasting period before study:
- Housing: 3/cage
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 55% ± 15%
- Air changes (per hr): 12-18 fold
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: To: 2013-10-23 to 2013-11-07 - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 10% (w/w)
- Amount of vehicle (if gavage): 10 mL/kg b.w.
DOSAGE PREPARATION (if unusual):
2000 mg/kg bw were achieved by administration of two times 1000 mg/kg bw, since a 20% w/w formulation was not homogenous based on trial formulations. - Doses:
- 2000 mg/kg bw, given as 2 dosages of 1000 mg/kg bw within 24 hours. The first on t=0 and the second on t=3 hours. Multiple dosages given within 24 hours are regarded as a single dose
- No. of animals per sex per dose:
- 6 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days - Frequency of observations: mortality: twice daily; clinical signs: before and immediately, 5, 15, 30 and 60 min, as well as 3, 6 and 24 hours after administration, followed once daily - Frequency of weighing: weekly - Necropsy of survivors performed: yes
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Remarks on result:
- other: 2/6 animals died on day 3 and 4, respectively
- Mortality:
- 2/6 animals died on day 3 and 4, respectively (one of three animals of each step)
- Clinical signs:
- other: Surviving animals showed no clinical signs
- Gross pathology:
- No pathological changes were observed at necropsy.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: CLP, EU GHS (Regulation (EC) No 1272/2008)
- Conclusions:
- The oral LD50 of C16-18 DMAPA amidoamine in female rats was > 2000 mg/kg bw.
- Executive summary:
In an acute oral toxicity study according to OECD guideline 423, adopted 17 December 2001 and EU method B.1 tris, May 2008, 6 female, fasted, approx. 9 weeks old CD(SD) strain rats were given a single oral dose of C16-18 DMAPA amidoamine (Amides, C16-18 (even numbered), N-[(dimethylamino)propyl]) in Propylene glycol by gavage at a dose of 2000 mg/kg bw and observed for 14 days.
The test substance was administeredas 2 dosages of 1000 mg/kg bw within 24 hours. The first on t=0 and the second on t=3 hours. Multiple dosages given within 24 hours are regarded as a single dose.
1/3 animals of each step died on day 3 and 4, respectively. No other clinical signs were noted in any of the animals. All surviving animals gained the expected weight at the end of the study period. No pathological changes were observed at necropsy.
Oral LD50 (rat, females) > 2000 mg/kg bw
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- For justification for read-across see endpoint summary "Aquatic toxicity".
- Reason / purpose for cross-reference:
- read-across source
- Statistics:
- Not reported
- Preliminary study:
- Not applicable
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 other: g/kg bw
- Remarks on result:
- other: no mortality during the observation period
- Mortality:
- No deaths were observed.
- Clinical signs:
- other: All animals appeared normal throughout the 24 h exposure period and the 14 d post-exposure observation period.
- Gross pathology:
- Not reported
- Other findings:
- Not reported
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of the test, the dermal LD50 value of the analogue source test substance was found to be > 2000 mg/kg bw.
- Executive summary:
A study was conducted to determine the acute dermal toxicity of the analogue source test substance amides, C8-18 and C18-unsatd., N,N-bis(hydroxyethyl) in male/female albino rabbit. The procedure was the modification of the techniques described in Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, compiled by the staff of the Division of Pharmacology, Food and Drug Administration.
2 g/kg bw of test material was applied (single application) to the abraded and intact skin of the test animals. The trunk of each animal was then encased in a sleeve of plasticized material to ensure contact of the test material for a 24 h period. Animals were observed immediately after dosing, and at 1, 6 and 24 h post-dosing. Following the 24 h exposure period, animals were observed for mortality, skin response and general behavior for 14 d.
No mortality was observed in this study. All animals appeared normal throughout the 24 h exposure period and the 14 d post-exposure observation period.
Under the conditions of the test, the dermal LD50 value was found to be > 2 g/kg bw.
It can be expected that the study results are also applicable to the target substance Amides, C16-18 (even numbered), N-[(dimethylamino)propyl].
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral toxicity data are available for the target substance C16-18 DMAPA amidoamine and for the source substance Stearic acid 3-(dimethylaminopropyl)amide. An acute dermal toxicity test is available with the source substance Amides, C8-18 and C18-unsatd., N,N-bis(hydroxyethyl). A justification for read-across is given below.
Acute oral toxicity
In an acute oral toxicity study according to OECD guideline 423, adopted 17 December 2001 and EU method B.1 tris, May 2008, 6 female, fasted, approx. 9 weeks old CD(SD) strain rats were given a single oral dose ofC16-18 DMAPA amidoamine(Amides, C16-18 (even numbered), N-[(dimethylamino)propyl]) in Propylene glycol by gavage at a dose of 2000 mg/kg bw and observed for 14 days.
The test substance was administered as 2 dosages of 1000 mg/kg bw within 24 hours. The first on t=0 and the second on t=3 hours. Multiple dosages given within 24 hours are regarded as a single dose.
1/3 animals of each step died on day 3 and 4, respectively. No other clinical signs were noted in any of the animals. All surviving animals gained the expected weight at the end of the study period. No pathological changes were observed at necropsy. Theoral LD50 (rat, females) was shown to be > 2000 mg/kg bw
Also the source substance used for read-across for the endpoints irritation, sensitisation, repeated dose toxicity, genetic toxicity and toxicity to reproduction , Stearic acid 3-(dimethylaminopropyl)amide, was of equally low oral toxicity as demonstrated by the following study on rats:
In an acute oral toxicity study according to OECD guideline 423, adopted 17 December 2001 and EU method B.1 tris, May 2008, 6 female, fasted, 8-9 weeks old Wistar strain rats were given a single oral dose of Stearic acid 3-(dimethylaminopropyl)amide in Propylene glycol by gavage at a dose of 2000 mg/kg bw and observed for 14 days.
The test substance was administered as 2 dosages of 1000 mg/kg bw within 24 hours. The first on t=0 and the second on t=3 hours. Multiple dosages given within 24 hours are regarded as a single dose.
2/6 animals died on day 2 and 3, respectively. Clinical signs shown by the animals found dead and surviving animals included lethargy, hunched posture, uncoordinated movements, piloerection, diarrhoea, chromodacryorrhoea, pallor, and/or ptosis.
The surviving animals had recovered from the symptoms between days 7 and 10.
The two animals found dead showed either slight weight gain or weight loss. 3/4 surviving females showed body weight loss between days 1 and 8. These animals again gained body weight between days 8 and 15. One surviving female showed body weight gain that was considered to be similar to that expected of normal untreated animals of the same age and strain.
One female found dead showed watery-turbid fluid in the stomach and watery-clear, yellowish fluid in the small intestines. The other female found dead showed a reduced size of the spleen. Pelvic dilation of the kidneys was noted in one surviving female. Other surviving females had no macroscopic abnormalities.Oral LD50 (rat, females) > 2000 mg/kg bw
Acute inhalation toxicity
Given that inhalation is not a relevant route of exposure, testing by the inhalation route is not necessary according to REACH Regulation Annex VIII 8.5.2 Column 2. Inhalation is not a relevant route of exposure to C16-18 DMAPA amidoamine. This applies to both workers and the general population and is due to the physicochemical properties of the substance and the nature of the products where it is used. C16-18 DMAPA amidoamine is a waxy solid paste. Generation of inhalable particles such as dust or aerosols is therefore not to be expected. Vaporisation needs not to be considered due to the substance’s very low vapour pressure of ca. 3.4E-08 Pa at 20°C. The generation of aerosols is excluded by technical means or product design. The substance is not used in spray applications. The most likely route of human exposure for workers and consumers is the dermal route. Results of laboratory animal studies show a low acute toxicity of closely related substances after oral and dermal exposure. Therefore the acute intrinsic toxic activity of C16-18 DMAPA amidoamine is considered to be low. The occurrence of a systemic toxicity relevant to humans after inhalation is unlikely and therefore the conduct of an acute inhalation toxicity study is unjustified.
Acute dermal toxicity
An acute dermal toxicity study has been conducted with the structurally similar substance Amides, C8-18 and C18-unsatd., N,N-bis(hydroxyethyl). This substance is structurally related toC16-18 DMAPA amidoamine and can be considered as a worst case due to more hydrophilic properties than C16-18 DMAPA amidoamine, which would favour dermal penetration.The test material (2000 mg/kg bw) was applied (single application) to the abraded and intact skin of male/female albino rabbits.The trunk of each animal was then encased in a sleeve of plasticized material to ensure contact of the test material for a 24 h period. Animals were observed immediately after dosing, and at 1, 6 and 24 h post-dosing. Following the 24 h exposure period, animals were observed for mortality, skin response and general behaviour for 14 d. No mortality was observed in this study. All animals appeared normal throughout the 24 h exposure period and the 14 d post-exposure observation period. Under the conditions of the test, the dermal LD50 value was found to be > 2000 mg/kg bw.
Endpoint conclusion
The testing of acute dermal toxicity of C16-18 DMAPA amidoamine is scientifically not justified as available reliable and relevant data from structurally related substances are used to fulfil this information requirement.
Based on the available information, the acute toxicity of C16-18 DMAPA amidoamine is low. There are no data gaps in acute toxicity. Even though there is no information on acute toxicity in humans, there is no reason to believe that the low acute toxicity observed in experimental animals would not be relevant for human health.
Justification for read-across
1. Read-across hypothesis and justification
This read-across is based on the hypothesis that source and target substances have similar toxicological properties because
they are manufactured from similar resp. identical precursors under similar conditions
the metabolism pathway leads to comparable products (amine backbone and long chain fatty acids) and non-common products predicted to have no toxicological effects (long chain fatty acids).
Therefore, read-across from the existing acute dermal toxicity study on the source substance is considered as an appropriate adaptation to the standard information requirements of Annex VIII 8.5.3 of the REACH Regulation for the target substance, in accordance with the provisions of Annex XI, 1.5 of the REACH Regulation.
The justification of the proposed read-across approach is elaborated in the next chapters.
2. Justification for read-across
2.1 Substance Identity
Table 1: Substance identities
|
Source substance |
Target substance |
Stearic acid 3-(dimethylaminopropyl)amide |
C16-18 DMAPA amidoamine Amides, C16-18 (even numbered), N-[(dimethylamino)propyl]) |
|
mono constituent substance |
UVCB substance |
|
CAS number |
7651-02-7 |
|
Chain length distribution |
< C16: < 1.6% C16: < 7% C18: > 89.8% > C18: < 1.6% |
C14: <= 5 % C16: 25-35 % C18: >= 61 % |
DMAPA |
<0.002% |
<=0.01% |
Substance descriptions
The target substanceC16-18 DMAPA amidoamine is a UVCB substance manufactured from saturated C16-18 fatty acids and N, N-dimethylpropylenediamine (DMAPA). It is composed of C16 and C18 amides of DMAPA, with C18 being the larger part (>/= 61%)
The source substanceStearic acid 3-(dimethylaminopropyl)amide is manufactured from octadecanoic acid andN, N-dimethylpropylenediamine. It is composed of mainly C18 amides (> 89.8%) of DMAPA and small amounts of the C16 amide (<7%).
2.2 Common breakdown products
The source substance Stearic acid 3-(dimethylaminopropyl)amide is the main component of the UVCB target substanceC16-18 DMAPA amidoamine. The only difference is the chain length distribution: the target substance also contains a significant amount of the C16 amide.
This is not considered to be of relevance for metabolism.Both substances are amides which after resorption may be hydrolysed by amidases resulting in free fatty acids and DMAPA. The carboxylic acids then are further degraded by the mitochondrial beta-oxidation process (for details see common text books on biochemistry). The fatty acids enter normal metabolic pathways and are therefore indistinguishable from fatty acids from other sources including diet. The amine compounds are not expected to be further metabolised, but excreted via the urine mainly unchanged.
2.3 Differences
The slight differences in fatty acid chain length (higher percentage of C16 in the target substance vs. corresponding higher percentage C18 in the source substance) are not considered to be of relevance for acute toxicity. This is proven by an equally low oral toxicity of > 2000 mg/kg bw for the source and target substances.
3. Physicochemical properties:
Table 2: Physicochemical properties
|
Source substance |
Target substance |
||
Endpoints |
Stearic acid 3-(dimethylaminopropyl)amide |
Result |
C16-18 DMAPA amidoamine |
Result |
Molecular weight |
|
368.64 g/mol |
|
340.59 - 368.64 |
Physical state at 20°C / 1013 hPa |
|
Solid (paste) |
|
Solid (waxy) |
Melting point |
OECD TG 102, RL1, non-GLP |
67.4°C |
OECD TG 102, RL1, non-GLP |
41.8°C |
Boiling point |
OECD TG 103, RL1, non-GLP |
412.3°C |
OECD TG 103, RL1, non-GLP |
320.5°C |
Surface tension |
ISO 4311, plate method, RL1, non-GLP |
37.86 mN/m at 0.22 g/L |
OECD TG 115, ring method, RL1, non-GLP |
26.7 mN/m at 2.7 mg/L |
Water solubility |
OECD TG 105, RL1, non-GLP |
10 mg/L at 20°C |
OECD guideline 105/EU method A.6, slow stirring method/HPLC, RL1, non-GLP |
3.65 mg/L at 23°C |
Log Kow |
|
|
Calculation (ACD/Labs Release 12.00, Product version 12.01 ) |
>6.6 |
EU method A.8, calculation based on solubility in n-Octanol and water; RL2, non-GLP |
2.01 at 20°C, pH7 |
Read-across from Stearic acid 3-(dimethylaminopropyl)amide |
|
|
Vapour pressure |
OECD TG 104, RL1, ISO17025 compliance |
3.4E-08 Pa at 20°C |
Read-across from Stearic acid 3-(dimethylaminopropyl)amide |
|
4. Toxicokinetics
Based on the very close structural relationship no relevant differences in toxicokinetics are expected.The source substance Stearic acid 3-(dimethylaminopropyl)amide is the main component of the UVCB target substanceC16-18 DMAPA amidoamine. The only difference is the chain length distribution: the target substance also contains a significant amount of the C16 amide.
Experimental toxicokinetic studies are not available for either the source substanceStearic acid 3-(dimethylaminopropyl)amide or the target substanceC16-18 DMAPA amidoamine. Based on physicochemical data and molecular weight,an oral absorption rate of 100% is assumed as a worst case default value in the absence of other data.
In a study according to OECD guideline 414 with dermal application of the source substance Stearic acid 3-(dimethylaminopropyl)amide systemic effects (lower body weight and lower food consumption) were noted. Thus, in the absence of detailed dermal penetration data it has to be assumed that dermal penetration may occur, and a dermal absorption rate of 100% is assumed as a worst case default value based on the physicochemical properties and on experimental toxicological data.
Based on the structure, both substances are likely to undergo hydrolysis by amidases, which in general have a broad substrate specificity. Hydrolysis of Stearic acid 3-(dimethylaminopropyl)amide would result in Stearic acid and 3-Aminopropyldimethylamine. Hydrolysis of the target substanceC16-18 DMAPA amidoamine would additionally produce Palmitic acid.Stearic acid as well as palmitic acid are likely to enter the normal fatty acid metabolism and may be broken down to carbon dioxide or two carbon fragments, or be re-esterified to triacylglycerols and either metabolised for energy or stored in adipose tissue.
In general, lower primary aliphatic amines are metabolised to the corresponding carboxylic acid and urea. The tertiary site would be expected to undergo oxidation mediated bycytochrome P-450 or mixed function amine oxidases.
5. Comparison of data from human health endpoints
5.1 Toxicity data of the target and source substances
Table 3: General toxicological profiles forStearic acid 3-(dimethylaminopropyl)amide andC16-18 DMAPA amidoamine
|
Source substance |
Target substance |
|
Endpoints |
Stearic acid 3-(dimethylaminopropyl)amide |
Result |
C16-18 DMAPA amidoamine |
Acute toxicity oral |
OECD TG 423, RL1,GLP |
LD50(rat) > 2000 mg/kg bw |
LD50(rat) > 2000 mg/kg bw |
Eye irritation |
OECD TG 405, RL1, GLP |
Category 1 (irreversible effects on the eye) |
No data; read-across |
|
OECD TG 437, RL1, GLP |
not severely irritating /not corrosive |
No data; read-across |
Skin irritation |
OECD TG 439, RL1, GLP |
not irritating |
not irritating |
|
OECD TG 404, RL1, GLP |
not irritating |
No data; read-across |
Sensitisation
|
OECD TG 406 (GPMT), RL1, GLP |
not sensitising |
No data; read-across |
Genotoxicity |
OECD TG 471, RL1, GLP |
Negative |
Negative |
OECD TG 467 (MLY), RL1, GLP |
Negative |
No data; read-across |
|
OECD TG 473 (Chromosome aberrations), RL1, GLP |
Negative |
No data; read-across |
|
Repeated dose toxicity oral |
Similar to OECD TG 407 (14 d DRF), rat, RL1, GLP |
clinical signs/mortality (all animals at 500 mg/kg bw/d were sacrificed for humane reasons); haematology (slightly lower red blood cell and higher reticulocyte counts in males at 50 and 200 mg/kg bw/d); clinical biochemistry (higher ALAT activity in 2 males at 50 mg/kg bw/d, 2 males and 1 female at 200 mg/kg bw/d, higher alkaline phosphatase activity in 1 female at 200 mg/kg bw/d, higher potassium level in males at 50 and 200 mg/kg bw/d) |
No data; read-across |
Repeated dose toxicity dermal |
Similar to OECD TG 411, rabbit, RL2, GLP |
NOAEL(systemic) = 200 mg/kg bw/d (highest dose administred) |
No data; read-across |
Reproduction / Developmental Toxicity Screening Test |
OECD TG 421, rat, RL1, GLP |
NOAEL(parental)= 70 mg/kg bw/d; NOAEL(fertility females)= 70 mg/kg bw/d; NOAEL (fertility males) = 200 mg/kg bw/d; NOAEL(development)= 200 mg/kg bw/d |
No data; read-across |
Prenatal developmental toxicity |
Similar to OECD TG 414, rabbit, RL2, GLP |
NOAEL(development)= 200 mg/kg bw/d (highest dose administered) |
No data; read-across |
Table 4: Toxicological data for Amides, coco, N,N-bis(hydroxyethyl)
|
Source substance |
Target substance |
|
Endpoint |
Amides, coco, N,N-bis(hydroxyethyl) |
Result |
C16-18 DMAPA amidoamine |
Acute toxicity dermal |
Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics (FDA), RL2, pre-GLP |
LD50(rabbit) > 2000 mg/kg bw |
No data; read-across |
For the target substance C16-18 DMAPA amidoamine an acute oral toxicity study according to OECD guideline 423, a dermal irritation study according to OECD Guideline 439 and a reverse gene mutation assay in bacteria according to OECD guideline 471 are available . As demonstrated above, the source substanceStearic acid 3-(dimethylaminopropyl)amide isthe main constituent of the target substance. The additional minor constituents with differing fatty acid chain lengths are not considered to influence the outcome of the toxicological studies what is demonstrated by similar results in the experimental studies (for further details please refer to the respective robust study summaries in IUCLID chapter 7.2.1).
For acute dermal toxicity, a read across to Amides, coco, N,N-bis(hydroxyethyl) is applied.This substance is structurally closely related toC16-18 DMAPA amidoamine and can be considered as a worst case due to more hydrophilic properties than C16-18 DMAPA amidoamine, which would favour dermal penetration.Thus, the read-across approach is considered to be valid.
5.2 Quality of the experimental data of the analogues:
Acute toxicity:
Reliable (RL1) GLP-compliant acute oral toxicity tests with the target substance C16-18 DMAPA amidoamine and the source substance Stearic acid 3-(dimethylaminopropyl)amide are available showing similar results.
For the assessment of acute dermal toxicity a pre-GLP test according to the Appraisal of the Safety of Chemicals in Foods, Drugs & Cosmetics with Amides, C8-18 and C18-unsatd., N,N-bis(hydroxyethyl) is available, which is considered to be reliable with restrictions (RL2).
The available data are sufficiently reliable and can be used in an analogue approach.
5.3 Classification and labelling
Concerning human health hazards, the source substance Stearic acid 3-(dimethylaminopropyl)amide is classified for irreversible effects on the eye (Eye Damage, Category 1, H318: Causes serious eye damage. / Xi; R41 Risk of serious damage to eyes). Based on the read-across, the target substance C16-18 DMAPA amidoamine will be classified accordingly.
6. Conclusion
The structural similarities between the source and the target substances and the similarities in their breakdown products presented above support the read-across hypothesis. Adequate and reliable scientific information indicates that the source and target substances and their subsequent degradation products have similar toxicity profiles.
The absence of acute toxicity of the source substance Stearic acid 3-(dimethylaminopropyl)amide is considered to be relevant also for the target substance C16-18 DMAPA amidoamine. No classification with respect to acute toxicity is required.
Justification for selection of acute toxicity – oral endpoint
OECD & EC guideline study, no deviations, GLP
Justification for selection of acute toxicity – inhalation endpoint
inhalation is not a relevant route of exposure
Justification for selection of acute toxicity – dermal endpoint
study according to Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics
Justification for classification or non-classification
Acute oral toxicity
Based on relevant, reliable and adequate data C16-18 DMAPA amidoamine does not need to be classified and labelled according to the CLP Regulation (EC) No 1272/2008 and Directive 67/548/EEC with respect to acute oral toxicity.
Acute dermal toxicity
Based on relevant, reliable and adequate data of read-across studies with a chemically related substance C16-18 DMAPA amidoamine does not need to be classified and labelled according to the CLP Regulation (EC) No 1272/2008 and Directive 67/548/EEC with respect to acute dermal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.